Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment

•Depression and the avolition-apathy domain of negative symptoms were related.•The diminished emotional expression domain of negative symptoms was associated with TNF-α, longitudinally.•Depression correlated with IL-6 in cross-section.•CRP was unrelated to any symptom domain.•Minocycline did not lea...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Brain, behavior, and immunity behavior, and immunity, 2021-01, Vol.91, p.498-504
Hauptverfasser: Krynicki, Carl R., Dazzan, Paola, Pariante, Carmine M., Barnes, Nicholas M., Vincent, Rachel C., Roberts, Alex, Giordano, Annalisa, Watson, Andrew, Suckling, John, Barnes, Thomas R.E., Husain, Nusrat, Jones, Peter B., Joyce, Eileen, Lawrie, Stephen M., Lewis, Shôn, Deakin, Bill, Upthegrove, Rachel
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Depression and the avolition-apathy domain of negative symptoms were related.•The diminished emotional expression domain of negative symptoms was associated with TNF-α, longitudinally.•Depression correlated with IL-6 in cross-section.•CRP was unrelated to any symptom domain.•Minocycline did not lead to an improvement in depression or negative symptoms. Immune dysfunction has been implicated in negative symptoms of schizophrenia and also in depression. These disorders are frequently co-morbid, with some symptoms such as anhedonia and apathy common to both. The anti-inflammatory agent minocycline may be ineffective in schizophrenia, but more positive effects have been seen in depression. Our aim was to investigate the role of immune dysfunction in depression and sub-domains of negative symptoms in schizophrenia by investigating their intercorrelation and the influence of treatment with minocycline. We analysed longitudinal data from 207 patients within 5 years of onset of schizophrenia, from the randomised double-blind, placebo-controlled trial of minocycline (BeneMin). Symptom ratings and circulating IL-6, C-reactive protein (CRP) and TNF-α concentrations were collected at baseline and repeated over twelve months. The sample was not stratified by CRP prior to randomisation. Positive and Negative Syndrome Scale composite ratings of avolition-apathy and diminished expression, Calgary Depression Scale total scores, and immune markers were examined cross-sectionally using Spearman’s rank, and longitudinally by linear mixed effect models that included body mass index and minocycline. Additionally, post hoc analysis of the sample stratified by elevated CRP (>1 mg/l and
ISSN:0889-1591
1090-2139
DOI:10.1016/j.bbi.2020.10.026